Clinical trials: Acquired Immune Deficiency Syndrome
Tuberculosis, Human Immunodeficiency Virus
Evaluating Accuracy, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons
Background: In Botswana, as in the rest of sub-Saharan Africa, undiagnosed TB or TB diagnosed late in the course of disease is thought to be the most common cause of death among HIV-infected persons.
- Trial name
- XPRES (NCT02538952)
- Testing
- Xpert device, Intensified TB Case Finding (ICF)
- Where
- Botswana
- Volunteers
- 18,696 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
HIV/AIDS, Gender
Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - Intervention Development
To address the critical scientific gaps in PrEP safety for transgender youth and to plan for appropriate implementation of PrEP in transgender youth communities, the study will be conducted in 3 integrated phases.
- Conditions
- HIV/AIDS, Gender, Behavior and Behavior Mechanisms
- Trial name
- NCT04077138
- Where
- 3 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hektoen Institute for Medical Research
High Risk for HIV
Zambia SiVET MMR Tdap-IPV
Participants will receive vaccination for measles, mumps, and rubella (MMR) and tetanus, diphtheria, pertussis, and inactivated polio (Tdap-IPV).
- Trial name
- SiVET (NCT02589678)
- Testing
- Tdap - IPV Vaccine, MMR Vaccine
- Where
- 2 sites in Zambia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV/AIDS
Development of a Couple-Based Mobile Health Intervention for Enhancing HIV Care Engagement Outcomes (N'Gage)
HIV/AIDS among Black men is a US public health crisis, emphasizing the urgency for increased research focus and intervention development.
- Trial name
- N'Gage (NCT03100643)
- Testing
- mHealth N'Gage mobile application
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV/AIDS, Tuberculosis, Pulmonary
INSTI's For The Management of HIV-associated TB
This study is being conducted to assess the antiretroviral activity of a fixed-drug, single tablet, combination of Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir alafenamide 25mg (Biktarvy®) dosed twice daily in HIV-1 infected…
- Trial name
- INSIGHT (NCT04734652)
- Testing
- Biktarvy®, TLD- fixed-drug combination single tablet
- Where
- South Africa
- Volunteers
- 122 people
- Sponsor
- Centre for the AIDS Programme of Research in South Africa
HIV Infections
Viral and Host Factors in the Transmission and Pathogenesis of HIV
To study the collection of blood from individuals known to be at high risk for HIV-infection or who have been recently infected with HIV.
- Trial name
- NCT00219947
- Testing
- blood draw
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Rockefeller University
HIV, Metabolic Diseases
Study of Lifestyle Modification in HIV Lipodystrophy
This study is designed to determine the effects of an intensive lifestyle modification program in patients with HIV and Metabolic Syndrome.
- Trial name
- NCT00111358
- Testing
- Lifestyle Modification, No lifestyle modification
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
HIV/AIDS
Impact of Metformin on Immuno-virologic Parameters in HIV
Non-diabetic, aviremic HIV-infected individuals on antiretroviral therapy (ART) will be randomized to metformin therapy or to observation for 72 weeks.
- Trial name
- NCT04500678
- Testing
- Metformin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Hawaii
Healthy Subjects, Infection, Human Immunodeficiency Virus
Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
Dolutegravir (DTG, GSK1349572) is a next-generation integrase inhibitor (INI) currently in phase 3 clinical trials for human immunodeficiency virus (HIV).
- Trial name
- NCT01366547
- Testing
- Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC)
To determine the toxic effects of AS-101 at various doses in patients with AIDS or AIDS related complex. Also to determine the effect of various doses of AS-101 on immune functions and the occurrence of infections in these…
- Trial name
- NCT00001006
- Testing
- AS-101
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infections
Computerized HIV/Sexually Transmitted Disease (STD) Prevention Program
The purpose of the current study is to test a computerized HIV/STD prevention program with heterosexual African Americans. The hypothesis is that those exposed to the program will increase their correct and consistent use of…
- Trial name
- TIPSS (NCT00947947)
- Testing
- Tailored Information Program for Safer Sex
- Where
- United States
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV-1
A Study of CL-197 Capsules in Healthy Participants
The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetic characteristics of CL-197 capsules in health conditions.
- Trial name
- NCT05944848
- Testing
- 1 mg CL-197 capsules
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Human Immunodeficiency Virus; HIV
An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
The purpose of this study is to study the kinetics (study of the rate of change) of immune recovery quality and function in stored plasma blood samples of treatment-naive (not previously treated with antiretroviral drugs)…
- Trial name
- NCT01541085
- Testing
- Darunavir/Ritonavir (DRV/r), Efavirenz (EFV)
- Volunteers
- 33 people
- Sponsor
- Janssen-Cilag S.p.A.
Human Immunodeficiency Virus Type 1
A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics
The purpose of this study is to compare the single-dose pharmacokinetics of rilpivirine (RPV) after intramuscular (IM) injection of rilpivirine long-acting parenteral formulation (RPV-LA) and 'aged' RPV-LA, in healthy adult…
- Trial name
- NCT02547870
- Testing
- Rilpivirine (RPV), Rilpivirine Long-Acting Parenteral Formulation (RPV-LA), Aged RPV-LA
- Where
- Belgium
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Janssen Infectious Diseases BVBA
HIV/AIDS, Sexual Behavior
Reducing HIV Risk in Urban Women: Soap Opera Videos on Video-Capable Cell Phones
Background: Love, Sex, and Choices (LSC) is a soap opera video series created to reduce HIV sex risk in women. Methods: LSC was compared to text messages in a randomized trial in 238 high-risk mostly Black young urban women.
- Conditions
- HIV/AIDS, Sexual Behavior, Woman's Role, Risk Behavior
- Trial name
- NCT03330522
- Testing
- Love, Sex, & Choices video series, Messages in text
- Where
- United States
- Volunteers
- 295 people
- Sponsor
- Northeastern University
Pneumonia, Pneumocystis Carinii, HIV Infections
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.
To provide trimetrexate glucuronate to immunosuppressed patients with Pneumocystis carinii pneumonia (PCP) for whom this investigational compound could provide significant medical benefit.
- Trial name
- NCT00002102
- Testing
- Trimetrexate glucuronate, Leucovorin calcium
- Where
- United States
- Sponsor
- U.S. Bioscience
Stigma, Social, HIV/AIDS
Transgender Education for Affirmative and Competent HIV and Healthcare
Educational workshops are an efficacious strategy to increase healthcare providers' ability to provide gender-affirming care for transgender (trans) people.
- Conditions
- Stigma, Social, HIV/AIDS, Health Care Acceptability
- Trial name
- TEACHH (NCT04096053)
- Testing
- TEACHH
- Where
- Canada
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Human Immunodeficiency Virus, HIV
Europe-Africa Research Network for Evaluation of Second-line Therapy
The trial aim is to ascertain what, if anything, needs to be combined with a boosted protease inhibitor (bPI) backbone in second-line therapy in order to maximize the chance of a good clinical outcome following WHO-defined…
- Trial name
- EARNEST (NCT00988039)
- Testing
- Aluvia + 2NRTIs, Aluvia + raltegravir, Aluvia monotherapy
- Where
- 14 sites in Kenya, Malawi and 3 more
- Volunteers
- 1,277 people
- Sponsor
- Justine Boles
HIV/AIDS
Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS
The aim of this pilot study is to assess the feasibility, efficacy and safety of Darunavir/ritonavir 800/100 mg once daily (DRV/r) monotherapy as a switch-maintenance strategy for patients receiving second-line ART at Yaoundé…
- Trial name
- MANET (NCT02155101)
- Testing
- Darunavir, ART with 2 NRTIs plus LPV/r (or ATV/r)
- Where
- Cameroon
- Volunteers
- 120 people
- Sponsor
- University of Liverpool
Human Immunodeficiency Virus Type 1 (HIV-1)
A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants
This sub-study will assess the pharmacokinetics (PK), safety, tolerability, virologic efficacy and health outcomes of CAB (GSK1265744) and RPV long acting (LA) in HIV-infected adult participants currently enrolled in the…
- Trial name
- NCT05896761
- Testing
- Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
- Where
- 32 sites in United States, Argentina and 5 more
- Volunteers
- 118 people
- Sponsor
- ViiV Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.